Basit öğe kaydını göster

Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorGogishvili, Miranda
dc.contributor.authorTurk, Haci M.
dc.contributor.authorGumus, Mahmut
dc.contributor.authorChen, Chieh-I
dc.contributor.authorIvanescu, Cristina
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorBondarenko, Igor
dc.contributor.authorCicin, Irfan
dc.contributor.authorHarnett, James
dc.contributor.authorMastey, Vera
dc.contributor.authorNaumann, Ulrike
dc.contributor.authorReaney, Matthew
dc.contributor.authorKonidaris, Gerasimos
dc.contributor.authorSasane, Medha
dc.contributor.authorBrady, Keri
dc.contributor.authorLi, Siyu
dc.contributor.authorGullo, Giuseppe
dc.contributor.authorRietschel, Petra
dc.contributor.authorSezer, Ahmet
dc.date.accessioned2021-12-10T11:41:16Z
dc.date.available2021-12-10T11:41:16Z
dc.date.issued2021
dc.identifier.citationGumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Harnett J., et al., "Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.", JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
dc.identifier.issn0732-183X
dc.identifier.othervv_1032021
dc.identifier.otherav_8e492aa8-7b9e-4cc6-b83b-87a0add76a41
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172416
dc.identifier.urihttps://doi.org/10.1200/jco.2021.39.15_suppl.9078
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.titlePatient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department, ,
dc.identifier.volume39
dc.identifier.issue15
dc.contributor.firstauthorID2769963


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster